558 related articles for article (PubMed ID: 28397698)
1. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
[TBL] [Abstract][Full Text] [Related]
3. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Osinusi A; Townsend K; Kohli A; Nelson A; Seamon C; Meissner EG; Bon D; Silk R; Gross C; Price A; Sajadi M; Sidharthan S; Sims Z; Herrmann E; Hogan J; Teferi G; Talwani R; Proschan M; Jenkins V; Kleiner DE; Wood BJ; Subramanian GM; Pang PS; McHutchison JG; Polis MA; Fauci AS; Masur H; Kottilil S
JAMA; 2015 Mar 24-31; 313(12):1232-9. PubMed ID: 25706232
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
6. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
[TBL] [Abstract][Full Text] [Related]
10. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
[TBL] [Abstract][Full Text] [Related]
11. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N; Reddy KR; Nelson DR; Lawitz E; Gordon SC; Schiff E; Nahass R; Ghalib R; Gitlin N; Herring R; Lalezari J; Younes ZH; Pockros PJ; Di Bisceglie AM; Arora S; Subramanian GM; Zhu Y; Dvory-Sobol H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Sulkowski M; Kwo P;
N Engl J Med; 2014 Apr; 370(16):1483-93. PubMed ID: 24725238
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Isakov V; Gankina N; Morozov V; Kersey K; Lu S; Osinusi A; Svarovskaia E; Brainard DM; Salupere R; Orlova-Morozova E; Zhdanov K
Clin Drug Investig; 2018 Mar; 38(3):239-247. PubMed ID: 29177645
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Naggie S; Fierer DS; Hughes MD; Kim AY; Luetkemeyer A; Vu V; Roa J; Rwema S; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Marks KM; Chung RT;
Clin Infect Dis; 2019 Jul; 69(3):514-522. PubMed ID: 31220220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]